Circle Pharma Announces Preclinical Data Poster Presentation of CID-078, a First-and-Only-in-Class Cyclin A/B RxL Inhibitor at the 2024 World Conference on Lung Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycle therapies, today announced that it presented a digital poster at the 2024 World Conference on Lung Cancer.

CID-078, Circle Pharma’s first-and-only-in-class cyclin A/B RxL inhibitor, demonstrated single-agent tumor regressions in both small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) preclinical models. Tumor models with high E2F targets and G2M checkpoint hallmark pathways scores and elevated levels of E2F1, cyclin B1 and ESPL1 demonstrate tumor growth inhibition and/or regression when treated with CID-078 dosed at clinically achievable doses. CID-078 activity correlated with E2F1 and ESPL1 expression and was consistent with the proposed mechanism of action of cyclin A/B RxL inhibition leading to DNA damage.

The data suggest that CID-078 holds promise as a monotherapy for patients with these cancers, which will be evaluated in a phase 1 clinical trial.

The digital poster can be viewed here.

About CID-078, Circle Pharma’s Cyclin A/B RxL Inhibitor Program

CID-078 is an orally bioavailable macrocycle with dual cyclin A and B RxL inhibitory activity that selectively targets tumor cells with oncogenic alterations that cause cell cycle dysregulation. In biochemical and cellular studies, Circle Pharma’s cyclin A/B RxL inhibitors have been shown to potently and selectively disrupt the protein-to-protein interaction between cyclins A and B and their key substrates and modulators, including E2F (a substrate of cyclin A) and Myt1 (a modulator of cyclin B). Preclinical studies have demonstrated the ability of these cyclin A/B RxL inhibitors to cause single-agent tumor regressions in multiple xenograft models.

About Circle Pharma, Inc.

South San Francisco-based Circle Pharma is advancing the discovery and development of intrinsically cell-permeable macrocycles that can be delivered by multiple routes, including oral administration. Circle Pharma’s MXMO™ platform combines structure-based rational drug design and advanced synthetic chemistry to develop a new generation of macrocycle therapies for challenging targets to address unmet clinical needs. Circle Pharma is focusing its development efforts on cyclins, which are master regulators of the machinery that controls the progression of cells through the cell cycle and are key drivers in many cancers.

To learn more about Circle Pharma, please visit www.circlepharma.com.